Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1770 participants
OBSERVATIONAL
2019-10-01
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
NCT02032368
DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC
NCT04967482
Adjuvant Radiotherapy Comparing TACE for Curative HCC
NCT02125396
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
NCT05025592
Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
NCT00646100
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hepatectomy alone
postoperative adjuvant transarterial chemoembolization
HCC patients received hepatectomy and PA-TACE.
PA-TACE
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
postoperative adjuvant transarterial chemoembolization
HCC patients received hepatectomy and PA-TACE.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmation of HCC diagnosis by pathological examination
* Curative surgical resection
Exclusion Criteria
* Macrovascular thrombosis or metastasis
* Perioperative mortality
* Unqualified image artifacts
* Tumor rupture
* MVI status not reported
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhujiang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Quan Xianyue
Academic Head of Department of Radiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Li X, Liang X, Li Z, Liang J, Qi Z, Zhong L, Geng Z, Liang W, Quan X, Liang C, Liu Z. A novel stratification scheme combined with internal arteries in CT imaging for guiding postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study. Int J Surg. 2024 May 1;110(5):2556-2567. doi: 10.1097/JS9.0000000000001191.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-KY-021-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.